Economy/Home · Economy

Samchundang Pharm Falls 1.78%, Alteogen Drops 2.50%, While Hanmi Pharma and Boryung Rise... Mixed Fortunes for Bio-Pharma Stocks

South Korean bio-pharma stocks showed sharply divided movements on the morning of the 16th, depending on the individual stock. Major bio names such as Samchundang Pharmaceutical, Alteogen, and Hanall Biopharma declined, while Hanmi Pharmaceutical, Boryung, and Celltrion held onto gains, leaving the

Wooil Shim
Staff Reporter
7 min read
Samchundang Pharm Falls 1.78%, Alteogen Drops 2.50%, While Hanmi Pharma and Boryung Rise... Mixed Fortunes for Bio-Pharma Stocks
CBC News

South Korean bio-pharma stocks showed sharply divided movements on the morning of the 16th, depending on the individual stock. Major bio names such as Samchundang Pharmaceutical, Alteogen, and Hanall Biopharma declined, while Hanmi Pharmaceutical, Boryung, and Celltrion held onto gains, leaving the sector mixed on individual supply and demand rather than moving in one direction.

■ Samchundang Pharm, Alteogen, and Other Major Stocks Weak

As of the morning of the 16th, Samchundang Pharmaceutical is trading at 154,700 won, down 2,800 won (1.78%) from the previous session. It opened at 158,700 won, touched an intraday high of 158,700 won, then fell to as low as 153,800 won. Selling pressure emerged from early in the session, keeping the stock in negative territory.

Alteogen is down 6,500 won (2.50%) from the previous session at 253,500 won. It opened at 261,500 won and rose to 262,000 won intraday before sliding to 252,000 won. Volume stands at about 212,000 shares.

Hanall Biopharma is down 1,050 won (2.16%) at 47,550 won. It rose to 48,900 won intraday before falling back to 47,300 won.

Green Cross is down 1.60% at 122,900 won, and Daewoong Pharmaceutical is down 1.18% at 108,500 won. Chong Kun Dang is down 0.76% at 65,400 won, and Dong-A ST is down 2.08% at 35,250 won.

Prestige Biologics is trading down a sharp 123 won (8.05%) from the previous session at 1,405 won. Prestige Biopharma is also down 2.01% at 5,840 won.

■ Hanmi Pharma, Boryung, LG Chem Rise... Celltrion Slightly Up

In contrast, Hanmi Pharmaceutical is up 5,500 won (1.11%) at 502,000 won, having risen as high as 515,000 won intraday, and Boryung is also showing strength, up 2.21% at 8,780 won.

Celltrion is up 300 won (0.17%) from the previous session at 177,800 won, holding slightly positive territory. Celltrion Pharma is down 0.38% at 39,100 won, showing divergent moves even among affiliated stocks.

LG Chem is trading up 6,500 won (2.39%) at 278,000 won, rising to 280,000 won intraday for a relatively strong performance.

■ Individual Supply and Demand Is Key... Focus on Mid- to Long-Term Rather Than Short-Term Swings

In today's bio-pharma trading, differences in individual stock supply and demand stand out more than any sector-wide direction. In particular, high-profile names such as Samchundang Pharmaceutical and Alteogen are falling together, drawing attention to intraday shifts in supply and demand.

Bio-pharma stocks can be influenced not only by company-specific catalysts such as clinical trials, drug approvals, technology transfers, and R&D schedules, but also by interest rates and investor sentiment toward growth stocks. Rather than judging the sector's or a company's mid- to long-term trajectory based on short-term price moves alone, investors should also check upcoming clinical and approval schedules, earnings, and the progress of contracts and business developments.

[This article is intended to provide general information on market and industry trends, and AI assisted in part with its writing. Clinical trials and R&D by bio-pharma companies may see changes in results and timelines, and the growth potential of the related industry does not guarantee revenue or earnings growth for individual companies. This is not a recommendation to invest in any specific stock, and the final investment decision and responsibility for it rest with the investor.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.